Figure 5.

The role of the LATPS in the prediction of immunotherapeutic benefits. The relative distribution of TIDE was compared between the LATPS-high and LATPS-low subgroups in the (A) training, (B) test, and (C) total cohorts. (D, E) Kaplan–Meier curve and ROC curve analyses of the LATPS for predicting immunotherapy benefits in GSE135222 cohort. (F, G) Kaplan–Meier curve and ROC curve analyses of the LATPS for predicting immunotherapy benefits in Nanfang Hospital cohort. LATPS, LUAD tumor microenvironment prognostic signature; ROC, receiver operating characteristic.